KURA
Kura Oncology, Inc.
$9.61
-2.54%
2026-10-23
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-4.69
EPS (TTM)
$-3.32
ROE
-167.7%
Revenue Growth (YoY)
36.5%
Profit Margin
0.0%
Debt/Equity
50.49
Price/Book
19.78
Beta
0.43
Market Cap
$957.2M
Avg Volume (10D)
2.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$13.90
60D Low
$8.82
Avg Volume
1.9M
Latest Close
$9.61
Get breakout alerts for KURA
Sign up for Breakout Scanner to receive daily notifications when KURA triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Kura Oncology, Inc. (KURA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KURA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KURA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.